Not long ago Commenced Affected person Enrollment in Period 1/2 CAReS Study of Art27.13 in the British isles Noted Favourable Pre-Medical Data Associated with Artelo’s
Tag: Biosciences
Interpace Biosciences Announces Full Year and Fourth Quarter 2020 Financial and Business Results
2020 Full Year Net Revenue of $32.4 Million Up 34% vs Prior Year; Fourth Quarter Net Revenue of $9.6M Million Up 129% vs Prior Year;
Brii Biosciences Closes US$155 Million Collection C Financing | Organization & Finance
DURHAM, N.C. & BEIJING–(Organization WIRE)–Mar 23, 2021– Brii Biosciences (“Brii Bio”), a multi-countrywide business acquiring ground breaking therapies for diseases with considerable unmet professional medical
IDEAYA Biosciences, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business Update
– Initiated Phase 1 clinical trial for IDE397, a potential best-in-class MAT2A inhibitor for patients having tumors with MTAP-deletion – Planning to present data at
Selecta Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
– First-in-human dose-escalation study to evaluate ability of ImmTOR™ to mitigate immunogenicity of AAV capsid initiated with initial data expected in the fourth quarter of
Caladrius Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Company demonstrates resilience despite COVID-19 challenges: Financial situation secure and development programs progressing Conference call begins today at 4:30 p.m. (ET) BASKING RIDGE, N.J., Feb.
Vedanta Biosciences Appoints Mark Mullikin as Main Financial Officer | Enterprise & Finance
CAMBRIDGE, Mass.–(Company WIRE)–Feb 8, 2021– Vedanta Biosciences, a foremost scientific-phase corporation creating a new group of therapies for immune-mediated health conditions based mostly on rationally
IFF to Total Merger With DuPont’s Nutrition & Biosciences Small business
NEW YORK–(Enterprise WIRE)–IFF (NYSE: IFF) to total the beforehand declared merger of IFF and DuPont’s Nourishment & Biosciences (“N&B”) business enterprise, pursuant to a Reverse